Justices Halt Ax Of Sanofi's Insulin Patents Over Arthrex

Law360 (February 11, 2020, 8:29 PM EST) -- Sanofi-Aventis can push back a Federal Circuit ruling that struck down its patents on the insulin medication Lantus until later this week, the U.S. Supreme Court has ruled, giving Mylan time to respond to Sanofi's bid to leverage the recent Arthrex ruling for its own case.

In an order Monday, the high court said that it would pause the Federal Circuit's ruling from going into effect and that Mylan has until Thursday to respond to Sanofi's application to stay the ruling. In November, the Federal Circuit affirmed the Patent Trial and Appeal Board's 2018 decisions invalidating two Sanofi patents covering Lantus,...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!